According to the most recent report by Renub Research, titled "Breast Cancer Screening Market, Global Forecast by Screening Test, Population, Countries, Company Analysis" breast cancer in female and sometimes in males forms within the cells of the breast; it's one amongst the most common cancer occurs in women after skin cancer. It also can happen in men but is most familiar with women around the world. Breast cancer begins with cells in milk-producing ducts. Consistent with doctors, around 5 per cent to 10 per cent of breast cancer cases are linked with a point mutation, which passes a radical generation. BRCA1 and BRCA2 are well-known breast cancer gene responsible for the chance of ovarian cancer and breast cancer.
The number of cases for breast cancer has increased since the previous few years, approx 60 % of death and 1.7 Million breast cancer cases diagnoses happen within the world per annum. The first reasons for this cancer are radiation exposure, consuming alcohol, lack of physical activities and obesity. Consistent with Renub Research analysis, the Global Breast Cancer Screening Market will grow with double-digit CAGR during the forecasted period, and also the market will grow to US$ 51.8 Billion by the end of the year 2025.
COVID-19 impact on the breast cancer Screening Market
Around the world, over a billion people are affected because of Coronavirus. The entire world is currently facing problems in healthcare, also as in the financial world. Most of the healthcare centres have reserved their team and resources for the treatment of COVID-19 patients. Thanks to this outbreak, women are avoiding diagnostics centre as lockdown are imposed by governments across the world. Other challenges of breast cancer screening are high medication costs, therapy-related adverse effects, and lengthy product approval times are answerable for curbing market growth.
Some of the most important breast cancer screening technologies which help to search out breast cancer after diagnosis are as follows. Breast cancer screening technologies are MRI, Ultrasound, and mammography screening. Mammography screening aims at minimizing the death rate from carcinoma by identifying unsuspected breast cancers early. The carcinoma mammography screening market is flourishing, driven by advances in technologies and delivery models, product innovations, increasing use of digital mammography equipment, and growing public awareness. Globally, awareness about carcinoma is increasing, with more women coming forward for his or her yearly mammograms after the age of 40 years.
Growing Incidence of breast cancer Globally
Breast cancer is the commonest cancer in women, in both developed and fewer developed countries. Consistent with WHO, it had been estimated that over 508,000 women died in 2011, thanks to breast cancer worldwide. Carcinoma incidence rates vary an excellent deal around the world. Generally, developed countries (such because us, England, and Australia) have higher rates than developing countries (such as Cambodia, Nepal, and Rwanda). There have been 14.1 million new cancer cases, 8.2 million cancer deaths, and 32.6 million people were living with cancer in 2012, within the world over. As a result, an increasing number of people are opting regular screening tests, which successively is driving the world carcinoma screening market. Furthermore, the rising awareness about the early detection of carcinoma and increasing government initiatives for carcinoma are driving the need to grow.
In India, NGOs, government agencies, and charity organizations are emphasizing on carcinoma awareness among the population to market early detection, provide comprehensive treatment module, and extend support for carcinoma management. As per the Globocan report estimation, in 2018, India reported ~162,468 new carcinoma cases, with 87,090 deaths because of the same.
In terms of region, the world carcinoma screening market will be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Countries like US, Canada, France, UK, Germany, Italy, Spain, Netherlands, Norway, Switzerland, China, India, Korea, Japan, Singapore, Thailand, Malaysia, Brazil, Australia, New Zealand, South Africa, United Arab Emirates, and Saudi Arabia capture the utmost share for the population with a higher probability of carcinoma. In 2016, these countries accounted for over 60% share of the world North America is anticipated to carry significant market share, as 70% of ladies within the U.S. undergo mammography. Germany is probably going to dominate the market in Europe, because of advanced health care infrastructure and government-supported screening programs. Availability of screening services privately health care and diagnostic centres are anticipated to drive the market in developing countries such as India.
Request a Free Sample Copy of the report: https://www.renub.com/request-sample-page.php?gturl=breast-cancer-screening-mammography-mri-and-ultrasound-market-and-forecast-worldwide-63-p.php
Market Summary:
By Screening Tests: Mammography is leading the market
This research report has covered the market and market share of Mammography, Magnetic Resonance Imaging (MRI) & Ultrasound.
By Countries: 23 Countries Breast Cancer Market is covered in the Report
The market and population of United States, Canada, France, United Kingdom, Germany, Italy, Spain, Netherlands, Norway, Switzerland, China, India, Korea, Japan, Singapore, Thailand, Malaysia, Brazil, Australia, New Zealand, South Africa, United Arab Emirates and Saudi Arabia are covered in this Research Report.
By Companies: This research report covers Overview, Initiatives & Recent Developments and Revenue analysis of AstraZeneca, Novartis, Sanofi, Pfizer and Bayer AG.
About the Company:
Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises of major players in Life Sciences, Information Technology, Telecom, Financial Services (Banking, Insurance), Energy, Retail, Manufacturing, Automotive, and Social sector. Our clients rely on our market analysis and data to make informed knowledgeable decisions. We are regarded as one of the best providers of knowledge. Our pertinent analysis helps consultants, bankers and executives to make informed and correct decisions.
Contact Us:
Renub Research
Phone No: +1 678-302-0700 (USA) | +91-120-421-9822 (IND)
Email: info@renub.com
Web: https://www.renub.com
Follow on Linkedin: https://www.linkedin.com/company/renub-research
Comments